Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 143 of the 146 references it cites were found in a registry or an index.

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

Open access

Abstract

The 2016 and 2021 World Health Organization 2021 Classification of central nervous system tumors have resulted in a major improvement in the classification of isocitrate dehydrogenase (IDH)-mutant gliomas. With more effective treatments many patients experience prolonged survival. However, treatment guidelines are often still based on information from historical series comprising both patients with IDH wild-type and IDH-mutant tumors. They provide recommendations for radiotherapy and chemotherapy for so-called high-risk patients, usually based on residual tumor after surgery and age over 40. More up-to-date studies give a better insight into clinical, radiological, and molecular factors associated with the outcome of patients with IDH-mutant glioma. These insights should be used today for risk stratification and for treatment decisions. In many patients with IDH-mutant grades 2 and 3 glioma, if carefully monitored postponing radiotherapy and chemotherapy is safe, and will not jeopardize the overall outcome of patients. With the INDIGO trial showing patient benefit from the IDH inhibitor vorasidenib, there is a sizable population in which it seems reasonable to try this class of agents before recommending radio-chemotherapy with its delayed adverse event profile affecting quality of survival. Ongoing trials should help to further identify the patients that are benefiting from this treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/noae107

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Schematic representation of the retinoblastoma (Rb) and receptor tyrosine kinase (RTK) pathway.
Figure 1. Schematic representation of the retinoblastoma (Rb) and receptor tyrosine kinase (RTK) pathway.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 146 references

Research works printed but not linked: 5

  1. Louis, 2021, The 2021 WHO classification of tumors of the central nervous system: A summary, Neuro-Oncology., 23, 1231, 10.1093/neuonc/noab106 · DOI · Paper page
  2. Tesileanu, 2021, Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma, Neuro-Oncology., 23, 1547, 10.1093/neuonc/noab088 · DOI
  3. Appay, 2019, CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas, Neuro Oncol., 21, 1519
  4. Aoki, 2018, Prognostic relevance of genetic alterations in diffuse lower-grade gliomas, Neuro Oncol., 20, 66, 10.1093/neuonc/nox132 · DOI · Paper page
  5. Mellinghoff, 2020, Ivosidenib in isocitrate dehydrogenase 1–mutated advanced glioma, J Clin Oncol., 38, 3398, 10.1200/JCO.19.03327 · DOI · Paper page

Cited by

See all 88

Metadata

Authors
van den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., Figarella Branger, D., Huang, R. Y., Weller, M., Mellinghoff, I. K., Cloughsey, T. F., Huse, J. T., Aldape, K., Reifenberger, G., Youssef, G., Karschnia, P., Noushmehr, H., Peters, K. B., Ducray, F., Preusser, M., & Wen, P. Y.
Affiliations
  • Brain Tumor Center at Erasmus MC Cancer Institute , Rotterdam,
  • Erasmus MC Cancer Institute (NL)
  • Northwestern University (US)
  • Deutsches Konsortium für Translationale Krebsforschung (DE)
  • Brigham and Women's Hospital (US)
  • University of California, Los Angeles (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Inserm (FR)
  • Department of Neuropathology, University Hospital Medicine and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ) , Heidelberg,
  • German Cancer Research Center (DE)
  • DFB Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d’Anatomie Pathologique et de Neuropathologie , Marseille,
  • University of Zurich (CH)
  • Department of Neurology, TC David Geffen School of Medicine at UCLA , Los Angeles ,
  • The University of Texas MD Anderson Cancer Center (US)
  • National Institutes of Health (US)
  • Düsseldorf University Hospital (DE)
  • Harvard University (US)
  • Henry Ford Hospital (US)
  • Duke University (US)
  • Inserm U1052, CNRS UMR5286, Université Claude Bernard Lyon , Lyon,
  • Medical University of Vienna (AT)
Venue
Neuro-Oncology
Published
2024-06-24
Volume
26
Issue
10
Pages
1805-1822
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W4399973103
Cited by
88
References
146
Citations by year
2026: 36 · 2025: 42 · 2024: 10
FWCI
6.66
Type
journal article
Language
en
Open access
Locations
  • Neuro-Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • HAL AMU (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Michigan State University
  • Institut National de la Santé et de la Recherche Médicale
  • Centre National de la Recherche Scientifique
  • Hospices Civils de Lyon
  • Deutschen Konsortium für Translationale Krebsforschung
  • Sorbonne Université
  • College of Engineering, Michigan State University
  • National Cancer Institute (P30CA008748, P50CA211015, R01CA279984, R01CA270027)
  • National Institute of Neurological Disorders and Stroke (R35NS105109)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Keywords
IDH-mutant glioma, isocitrate dehydrogenase inhibitors, vorasidenib, tumor grade, age, tumor enhancement, extent of resection, risk stratification, radiotherapy, chemotherapy, treatment decision-making, overall survival, quality of survival
MeSH terms
Clinical Decision-Making, Age Factors, Brain Neoplasms, Enzyme Inhibitors, Glioma, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? https://app.cochat.ai/papers/10.1093/neuonc/noae107
The paper
van den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., Figarella Branger, D., Huang, R. Y., Weller, M., Mellinghoff, I. K., Cloughsey, T. F., Huse, J. T., Aldape, K., Reifenberger, G., Youssef, G., . . . Wen, P. Y. (2024). The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? Neuro-Oncology. https://doi.org/10.1093/neuonc/noae107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.